Can I Switch From The Wegovy Injection To The Wegovy Tablet?
 - Guide | Cured Pharmacy

Can I Switch From The Wegovy Injection To The Wegovy Tablet?

Wegovy® Oral Tablets (Semaglutide Pill)

Featured Product

Wegovy® Oral Tablets (Semaglutide Pill)

From £83.00£63.99UK-based prescribers · Discreet delivery · Free private prescription
Start Assessment →✓ Lowest price guarantee
DISCOUNT CODE: FIRST20

£20 off for new patients

Tarun Kumar, Prescribing Pharmacist at Cured Pharmacy

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: 22 June 2026

Last Updated: 13 August 2026

If you have been using the Wegovy injection pen to manage your weight and have heard that an oral version is on the horizon, you are not alone in wondering what this change might mean for your treatment. The move from Wegovy injection to Wegovy tablets is one of the most talked-about developments in weight management medicine in the UK right now, and for good reason. Many people who rely on weekly injections find them inconvenient, anxiety-inducing, or simply hard to sustain long term. The arrival of an oral semaglutide tablet offers a genuine alternative — but understanding the differences in how these two formats work, how they compare in effectiveness, and how to switch safely is essential before making any changes to your treatment plan.

Quick Summary

Switching from a weekly Wegovy injection to a daily oral tablet form of semaglutide is a significant step that requires careful consideration of bioavailability, dosing, and lifestyle factors. Both delivery methods contain the same active ingredient, semaglutide, but they behave differently in the body and suit different patient needs.

  • Wegovy tablets contain the same active ingredient as the injection — semaglutide — but are taken orally rather than by subcutaneous injection.
  • Oral semaglutide has lower bioavailability, meaning higher doses are required to achieve comparable effects to the injection.
  • Tablets must be taken on an empty stomach, first thing in the morning, with no more than 120ml of plain water, to ensure proper absorption.
  • Switching should always be supervised by a prescriber, as the dosing schedule differs between formulations.
  • Many patients prefer the tablet format due to needle phobia, convenience, and ease of travel — making it a viable long-term option for many people.

🔄 Wegovy Transition Readiness Checker

Answer these quick questions to see how ready you might be to switch from the Wegovy injection to the tablet form. This is for informational purposes only — always consult your prescriber before making any changes.

1. Do you have difficulty self-injecting or experience needle anxiety?

2. Can you reliably take a tablet first thing in the morning, on an empty stomach?

3. Do you travel frequently and find carrying injection pens inconvenient?

4. Are you currently at a stable dose on the Wegovy injection with no recent dose changes?

Table of Contents

What is the Wegovy Tablet and How Does It Differ from the Injection?

Wegovy, in its injectable form, has been available in the UK since 2023 and is a weekly subcutaneous injection containing semaglutide — a glucagon-like peptide-1 (GLP-1) receptor agonist. The injection is administered into the fatty tissue of the abdomen, thigh, or upper arm once per week, and delivers semaglutide directly into the bloodstream with a high degree of bioavailability, estimated at around 89%.

The Wegovy tablet, by contrast, is an oral form of semaglutide that must be absorbed through the gastrointestinal tract. This is no small feat — peptide molecules like semaglutide are normally broken down by stomach acid before they can reach the bloodstream. To overcome this, the oral version is co-formulated with a compound called SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]), which facilitates absorption through the lining of the stomach. This makes it one of the most innovative pharmaceutical advances in the weight loss medication space.

The critical difference is absorption efficiency. Because oral semaglutide has to survive the digestive process, its bioavailability is considerably lower than the injection — approximately 0.4% to 1% without the SNAC facilitator, and still significantly lower than the injection even with it. This means that higher doses are prescribed in tablet form to compensate. The experience of the Wegovy injection to wegovy tablets transition is therefore not a simple like-for-like swap; the dosing strategy is fundamentally different.

  • The injection delivers semaglutide subcutaneously for slow, consistent release throughout the week.
  • The tablet delivers semaglutide orally in a daily dose, with a sharp absorption peak in the morning.
  • Both work by mimicking GLP-1 to reduce appetite, slow gastric emptying, and regulate blood sugar.
  • The SNAC compound in oral semaglutide enables stomach absorption rather than intestinal absorption.
  • Oral tablets must be taken with no more than 120ml of plain still water, on an empty stomach, at least 30 minutes before eating.

Why People Are Switching from Wegovy Injection to Wegovy Tablets

There are deeply personal and practical reasons why so many patients are asking about switching from the Wegovy injection to oral tablets. Needle phobia is one of the most common. Studies consistently show that a significant proportion of patients who would benefit from injectable therapies avoid them altogether due to a fear of self-injection. For these individuals, an oral alternative removes a major psychological barrier and could dramatically improve adherence to treatment.

Convenience is another powerful motivator. Carrying an injection pen, ensuring it is stored correctly (between 2°C and 8°C when unopened, and used within 28 days once opened), and managing injections whilst travelling can be genuinely stressful. A tablet, by comparison, slips into a handbag or travel wash bag without any of these requirements. For people with busy lives, this flexibility is not a minor detail — it is what makes the difference between continuing treatment and stopping.

There is also a growing number of patients who experience persistent injection site reactions — bruising, lumps, or soreness — that make weekly injections increasingly uncomfortable. The Wegovy injection to wegovy tablets pathway offers these patients a way to continue benefiting from semaglutide therapy without the ongoing skin irritation. This is a real, often underreported clinical problem that the oral format directly resolves.

  • Needle phobia and injection anxiety affect an estimated 10% of the general population in the UK.
  • Oral tablets eliminate the need for sharps disposal and cold-chain storage once out of the fridge.
  • Patients who have experienced injection site lipodystrophy may find tablets more comfortable long term.
  • For those managing type 2 diabetes alongside obesity, an oral GLP-1 therapy already exists (Rybelsus), providing a strong evidence base for oral semaglutide.
  • The daily routine of a tablet can feel more familiar and less medicalised than a weekly injection.

How to Switch from the Injection to the Tablet Safely

The most important rule when transitioning from the Wegovy injection to Wegovy tablets is this: do not attempt to switch without speaking to a prescriber first. This is not a decision that should be made independently because the dosing is not directly equivalent. If you simply stop your injection and start taking tablets at a dose you have chosen yourself, you risk either under-treating your condition or experiencing amplified side effects from an inappropriate dose.

A UK-based prescriber, such as those at Cured Pharmacy, will assess your current injection dose, your weight loss progress, and your overall clinical picture before recommending a tablet dose. Generally, the dose escalation protocol for the tablet form starts lower and titrates upward over several weeks. This mirrors the approach taken with the injection, where patients start at 0.25mg weekly and increase gradually to 2.4mg — the approved maintenance dose for weight management.

Timing of the switch also matters. Most prescribers will advise completing your current injection pen before starting the tablet, rather than switching mid-pen. This avoids unnecessary waste and ensures a cleaner starting point. If you have recently increased your injection dose, it may be advisable to remain at that dose for at least four weeks before transitioning to allow your body to stabilise before introducing a new formulation.

  • Always complete a formal prescriber consultation before switching formulations.
  • Your prescriber will review your current dose, any side effects, and your weight loss trajectory.
  • Expect a fresh dose titration schedule — tablets are not interchangeable at the same milligram dose.
  • Take the tablet first thing in the morning with no more than 120ml of still water on a completely empty stomach.
  • Wait at least 30 minutes (ideally 60 minutes) after taking the tablet before eating or drinking anything else.
  • Do not crush, break, or chew the tablet — swallow it whole.

Effectiveness Comparison: Injection vs Oral Tablet

One of the most frequently asked questions by patients considering the Wegovy injection to wegovy tablets switch is: will I lose as much weight with the tablet? This is a completely valid concern, and the honest answer is nuanced. Clinical trial data suggests that injectable semaglutide at 2.4mg weekly produces superior weight loss outcomes compared to oral semaglutide at currently studied doses — but the oral form still produces clinically meaningful weight loss that is significantly better than diet and lifestyle alone.

The landmark STEP 1 trial, published in the New England Journal of Medicine, demonstrated that injectable semaglutide at 2.4mg produced an average weight reduction of approximately 14.9% of body weight over 68 weeks. Comparable studies with oral semaglutide for weight management (the OASIS 1 trial) showed an average weight loss of around 15.1% with oral semaglutide 50mg daily — a notably competitive result. It is worth noting that the oral doses studied in OASIS 1 are considerably higher than those used in diabetes management (Rybelsus), which explains some of the confusion around dose equivalence.

In 2026, the evidence base for oral semaglutide in weight management continues to grow, and its profile looks increasingly favourable for patients who cannot or do not wish to use the injectable form. The Wegovy injection to wegovy tablets transition should therefore not be seen as a step down in treatment — for many patients, it is simply a different, and equally valid, way of receiving the same therapy.

  • OASIS 1 trial showed oral semaglutide 50mg daily produced approximately 15.1% body weight reduction over 68 weeks.
  • STEP 1 trial showed injectable semaglutide 2.4mg produced approximately 14.9% body weight reduction over 68 weeks.
  • Both forms produce meaningful improvements in blood pressure, blood glucose, and cholesterol levels.
  • Adherence to the strict morning fasting protocol is critical for oral semaglutide to achieve its full effect.
  • Individual responses vary — some patients may find the injection more effective, whilst others thrive on the oral format.

Side Effects to Be Aware of When Switching

When transitioning from the Wegovy injection to Wegovy tablets, patients should be aware that the side effect profile of both formulations is broadly similar, as both contain semaglutide. The most commonly reported side effects include nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These tend to be most pronounced during dose escalation and typically diminish as the body adjusts to the medication over several weeks.

However, there is an important nuance when switching. Because the oral tablet delivers semaglutide in a daily dose rather than a sustained weekly release, some patients notice slightly different gastrointestinal patterns when they first transition. The daily peak in drug concentration that occurs with oral administration can feel more intense initially, particularly in the first few weeks. This is why starting at a lower tablet dose — even if you were previously on a high injection dose — is prudent clinical practice.

There are also practical considerations around taking the tablet correctly. If the strict fasting protocol is not followed — for example, if you eat before the tablet or take it with food or a full glass of water — absorption can be significantly reduced, which may cause inconsistency in your treatment response. Some patients mistakenly interpret this reduced absorption as a side effect or lack of efficacy, when in fact it is an adherence issue. Getting the morning routine right from day one is arguably the most important factor in achieving good outcomes with the oral formulation.

  • Nausea is the most common side effect and usually peaks in the first 4 to 8 weeks of treatment.
  • Starting at a lower tablet dose can help minimise the intensity of gastrointestinal side effects during transition.
  • Staying well hydrated throughout the day (after the 30-minute fast window) can help manage nausea and constipation.
  • If you experience persistent vomiting or are unable to keep the tablet down, contact your prescriber promptly.
  • Rare but serious risks — including pancreatitis and gallbladder disease — apply to both the injection and the tablet and should be discussed with your prescriber at consultation.

Wegovy Tablets in the UK: Availability and Prescribing in 2026

The UK pharmaceutical landscape for oral semaglutide is evolving rapidly in 2026. Rybelsus (oral semaglutide) has been licensed in the UK for type 2 diabetes management for several years, and the data generated from that patient population has provided a strong foundation for understanding how oral semaglutide behaves in a clinical setting. The specific Wegovy oral tablet formulation — targeted at weight management rather than diabetes — represents an exciting next step.

In the UK, prescribing of weight management medications requires a clinical assessment to confirm eligibility. Patients must typically have a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. These eligibility criteria apply whether the patient is starting treatment for the first time or switching from another GLP-1 formulation such as the Wegovy injection to wegovy tablets. A licensed prescriber must confirm ongoing suitability at each stage.

At Cured Pharmacy, we work with GPhC-registered prescribers who are experienced in GLP-1 weight management therapies and can support your transition from injectable to oral semaglutide safely and efficiently. Prescriptions are issued following a thorough online consultation, and discreet delivery is available across the UK. Pre-ordering the Wegovy oral tablet now ensures you are among the first to receive it once it becomes available to dispense, without losing momentum in your weight loss journey.

  • Wegovy oral tablets are currently available for pre-order through Cured Pharmacy at From £83.00£63.99 per pack.
  • A valid UK private prescription is required — Cured Pharmacy can provide this following an online consultation.
  • Eligibility criteria for oral semaglutide are the same as for the injectable form in a weight management context.
  • Patients already prescribed injectable Wegovy can transition with prescriber support — no need to restart from scratch clinically.
  • Discreet packaging and free private prescriptions are included with every order at Cured Pharmacy.

Comparison Table: Wegovy Injection vs Wegovy Tablet

Feature Wegovy Injection (2.4mg weekly) Wegovy Tablet (Oral Semaglutide)
Active Ingredient Semaglutide Semaglutide
Administration Route Subcutaneous injection (abdomen, thigh, arm) Oral tablet, swallowed whole
Dosing Frequency Once weekly Once daily
Bioavailability Approximately 89% Lower; enhanced by SNAC co-formulation
Storage Requirements Refrigerate unopened; use within 28 days once opened Room temperature; no cold chain required
Average Weight Loss (Clinical Trials) ~14.9% body weight (STEP 1) ~15.1% body weight (OASIS 1 at 50mg daily)
Needle Required Yes No
Fasting Requirement None Must be taken on empty stomach with ≤120ml plain water
Suitable for Needle Phobia No Yes
Travel Convenience Requires cool bag; airport restrictions may apply No refrigeration; easy to travel with
Sharps Disposal Required Not required
Cost at Cured Pharmacy Available on consultation From From £83.00£63.99 (pre-order)

Key Takeaways

  • Both the Wegovy injection and the Wegovy tablet contain semaglutide and work in the same way — by activating GLP-1 receptors to reduce appetite and support weight loss.
  • The oral tablet requires a strict morning fasting protocol to ensure adequate absorption — this is the single most important adherence factor for the oral format.
  • Clinical trial data from 2026 and prior years suggests the oral tablet can achieve comparable weight loss results to the injection when taken correctly and at appropriate doses.
  • Switching should always be done under prescriber supervision, with a fresh titration schedule and a clear plan for monitoring progress.
  • Wegovy oral tablets are now available for pre-order at Cured Pharmacy, with UK-based prescribers, discreet delivery, and a free private prescription included.

When to Seek Professional Advice

You should always seek professional advice before making any changes to your Wegovy treatment. This includes switching from the injection to the tablet, increasing or decreasing your dose, or stopping treatment altogether. Specific situations where you should contact a prescriber urgently include: persistent severe nausea or vomiting lasting more than 48 hours, severe abdominal pain that radiates to the back (a potential sign of pancreatitis), sudden vision changes, signs of a serious allergic reaction such as facial swelling or difficulty breathing, or any rapid and unexplained deterioration in your general health.

If you are currently pregnant, planning a pregnancy, or breastfeeding, semaglutide in any form is not appropriate and must be discontinued in advance of conception. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 should not take semaglutide at all, regardless of the route of administration.

For general questions about the Wegovy injection to wegovy tablets transition, the team at Cured Pharmacy is available to help. Our GPhC-registered prescribers can complete a full online consultation, review your medical history, and confirm whether you are eligible to switch. You can also explore how semaglutide supports broader cardiometabolic health — and for general health support supplements that complement your wellness journey, consider BetterYou Vitamin D3+K2 Oral Spray, which supports immune function and metabolic health alongside your weight management treatment.

Scientific References

  1. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. STEP 1 Trial. [Accessed 13 August 2026]
  2. Knop FK, et al. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. [Accessed 13 August 2026]
  3. Medicines and Healthcare products Regulatory Agency (MHRA). (2026). Guidance on prescribing GLP-1 receptor agonists for weight management in the UK. MHRA.gov.uk. [Accessed 13 August 2026]
  4. Semaglutide for managing overweight and obesity (TA875), NICE Technology Appraisal Guidance, 2023 [Accessed 13 August 2026]
  5. Wegovy 0.25mg–2.4mg solution for injection SmPC, Novo Nordisk, Electronic Medicines Compendium, 2023 [Accessed 13 August 2026]
  6. Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial), The Lancet, 2021 [Accessed 13 August 2026]
  7. Davies M et al., Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2), New England Journal of Medicine, 2021 [Accessed 13 August 2026]
  8. MHRA approves Wegovy (semaglutide) for weight management in the UK, MHRA, 2023 [Accessed 13 August 2026]
  9. Oral semaglutide and weight management: what the evidence says, Diabetes UK, 2023 [Accessed 13 August 2026]

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today.

Once you complete a short online assessment, you will be able to choose your preferred treatment and quantity from a list of safe, medically approved options tailored to you.

Start My AssessmentReturning Customer?Log In to Your Account

Frequently Asked Questions

How long does it take for Wegovy tablets to start working?

Wegovy tablets typically begin working within the first week of use, but meaningful weight loss results are usually seen after 4 to 8 weeks of consistent dosing. Clinical data suggests the full appetite-suppressing effect builds gradually, with most patients noticing significant changes within the first 12 weeks of treatment.

Is switching from the Wegovy injection to the tablet form safe?

Switching from the Wegovy injection to Wegovy tablets is considered safe when done under the guidance of a qualified prescriber. Both forms contain semaglutide, the same active ingredient, but the dosing and absorption differ. Your prescriber will advise on the appropriate tablet dose to match your current injection dose.

Can you take Wegovy tablets with other medications?

Wegovy tablets can interact with certain medications, particularly oral drugs that require precise absorption timing, since semaglutide can slow gastric emptying. You should always inform your prescriber about every medication you take, including supplements, before switching from the Wegovy injection to Wegovy tablets to avoid potential interactions.

What is the dose of Wegovy tablets compared to the injection?

The dose of Wegovy tablets differs from the injection because oral bioavailability of semaglutide is lower. Oral semaglutide doses are typically higher in milligrams to achieve comparable blood levels. Your prescriber will calculate an equivalent dose when transitioning from the Wegovy injection to Wegovy tablets based on your current injection dose and clinical response.

Back to blog